Breast cancer subtype has to be accounted for to predict response to neoadjuvant chemotherapy based on radiomic features in 18F-FDG PET

1236Objectives: Breast cancer (BC) is a heterogeneous disease and various BC subtypes account for part of this heterogeneity. We investigated whether radiomic features (RF) calculated from FDG PET also reflected BC heterogeneity and determined whether RF combined with other important BC prognostic factors could predict pathological complete response (pCR) in BC patients who underwent neoadjuvant chemotherapy (NAC). Methods: Texture analysis was performed in a cohort of BC patients who underwent PET/CT at initial staging. Part of these patients then underwent NAC consisting of an association of taxanes and anthracyclines with or without trastuzumab in tumors expressing HER2. For these patients, pCR was assessed using Sataloff classification defined as TA-NA/B. PET/CT images (GE Discovery 690 PET/CT scanner, OSEM reconstruction, voxel size of 2.7 x 2.7 x 3.3 mm3) were obtained 60 to 80 min after injection of 3-3.5 MBq/kg of 18F-FDG when capillary blood glucose was below 11 mMol/L. SUVs (max, mean, peak), 4 histogram-based features and 31 textural indices (TI) were calculated after automatic segmentation of the tumor (40% of SUVmax using LIFEx software). Anova tests with post-hoc analysis using correction for multiple testing were used to compare RF and BC factors (AJCC staging, presence of elevated tumor markers, Ki-67 expression, tumor grade, presence of necrosis, of in situ carcinoma and of an inflammatory stroma) between subtypes: HER2+, Luminal A, Luminal B HER2-, Luminal B...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Breast Cancer Posters Source Type: research

Related Links:

Authors: Jang Y, Cho EY, Cho SY Abstract Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) negative. Here, we present a case of HER2-positive MC with an unusual signet ring cell differentiation. It is very rare that a breast tumor consists entirely of signet ring cells. The tumor showed pathologic complete response (pCR) after neoadjuvant chemotherapy with trastuzumab and pertuzumab. pCR of HER2-po...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
AbstractBreast cancer is a highly heterogeneous disease. The efficacy of tailored therapeutic strategies relies on the precise detection of diagnostic biomarkers by immunohistochemistry (IHC). Therefore, considering the increasing incidence of breast cancer cases, a concomitantly time-efficient and accurate diagnosis is clinically highly relevant. Microfluidics is a promising innovative technology in the field of tissue diagnostic, enabling for rapid, reliable, and automated immunostaining. We previously reported the microfluidic-based HER2 (human epidermal growth factor receptor 2) detection in breast carcinomas to greatl...
Source: Virchows Archiv - Category: Pathology Source Type: research
Abstract PURPOSE: Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to analyze the clinicopathological characteristics and clinical outcomes of coexisting DCIS component in IDC and its clinical significance according to molecular subtypes. METHODS: Data from 3001 patients with IDC (79.4%) and IDC/DCIS (20.6%) who underwent surgery from January 2009 to June 2016 were retrospectively assessed. The clinical outcomes of IDC with coexistent DCIS in different molecular subtypes were evaluated. RESULTS: IDC/DCIS patients were more likely to be younger (P 
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
In this study Pari-Institute for Cancer Research (Pari-ICR) was derived from the primary breast tumorof a 36-years old patient with invasive ductal carcinoma. We characterized the cell line by examining morphology,expression of different markers, and functional profile. Immunocytochemistry showed that this cell line does not expressestrogen and progesterone receptors as well as human epidermal growth factor receptor 2 (HER2). Pari-ICR cell lineexpresses high levels of Vimentin, Ezrin, and S100 but does not express EpCAM, Cytokeratin19, Pan-cytokeratin,Nestin, and Desmin. Its doubling time of Pari-ICR was about 22h and was ...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient w...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
ita Diterpenoid alkaloids are isolated from plants of the genera Aconitum, Delphinium, and Garrya (Ranunculaceae) and classified according to their chemical structures as C18-, C19- or C20-diterpenoid alkaloids. The extreme toxicity of certain compounds, e.g., aconitine, has prompted a thorough investigation of how structural features affect their bioactivities. Therefore, natural diterpenoid alkaloids and semi-synthetic alkaloid derivatives were evaluated for cytotoxic effects against human tumor cells [A549 (lung carcinoma), DU145 (prostate carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen recep...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Authors: Goller SS, Markert UR, Fröhlich K Abstract Breast cancer is one of the most common malignancies which appear during pregnancy. Since women are increasingly not giving birth until they are at a more advanced age, it can be assumed that the incidence of pregnancy-related breast cancers will continue to increase in the future. Because of pregnancy-induced changes and conservative diagnosis, these carcinomas are frequently not detected until they are at an advanced stage and thus generally require systemic adjuvant therapy. The available data on optimal chemotherapeutic management are limited. Particularl...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
CONCLUSION: This is the first reported Australian experience using neoadjuvant dual anti-HER2 and taxane therapy for HER-2 positive nonmetastatic breast cancer. The authors have demonstrated favorable pCR rates for invasive disease compared to the NEOSPHERE trial (68% vs 46%), with reasonable patient tolerability. Larger collaborative data sets are required to fully evaluate correlation of pCR with survival outcomes, and cost-effectiveness. National funding models need to be considered. PMID: 31218842 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Asia Pac J Clin Oncol Source Type: research
AbstractPatients with breast cancer desire to avoid chemotherapy-induced alopecia because it induces mental stress during treatment. Scalp cooling can suppress chemotherapy-induced alopecia without increasing the risk of scalp metastasis; however, in certain cases, alopecia cannot be prevented. The use of properly fitted scalp cooling caps has not yet been explored in Asian patients. Here, we report a case of hair regrowth using a properly fitted scalp cooling cap during adjuvant chemotherapy for breast cancer. A 51-year-old Japanese woman who was recalled by screening mammography for grouped amorphous calcifications and a...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Conclusion: This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemistry | Chemotherapy | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nuclear Medicine | PET Scan | Statistics